AbbVie’s next-gen Crohn’s disease combo beats Skyrizi in phase 2 trial
AbbVie presents phase 2 trial data for its next-generation Crohn's disease therapy, ABBV-466.
Velocity
How fast coverage is spreading — measured hourly from article rate × source diversity. How this works →
The brief
Recent reporting outlines significant developments regarding pharmaceutical treatments for Crohn's disease and inflammatory bowel disease, centered on announcements from AbbVie. According to coverage from outlets including Fierce Biotech, Investing News Network, and grafa.com, data has been presented for ABBV-466, described as a novel dual-targeting therapy. The phase 2 trial results indicate that this next-generation combination treatment achieved higher endoscopic remission rates compared to either anti-IL-23 or anti-beta-7 monotherapy in patients suffering from moderate to severe Crohn's disease. Additional specifics from grafa.com point to an achieved remission figure of forty and a half percent within the trial parameters. Simultaneously, coverage from Yahoo Finance and MedPage Today highlights concurrent presentations at the UEGW 2026 event.
These reports detail long-term clinical and endoscopic outcomes across inflammatory bowel disease for established medications Skyrizi, known generically as risankizumab, and Rinvoq, known as upadacitinib. MedPage Today specifically emphasizes the outcomes of subcutaneous risankizumab induction for Crohn's disease patients. The concurrent rollout of these data sets positions the newer experimental compound alongside the company's existing portfolio of targeted biological therapies in medical discourse. Context provided by the aggregated headlines situates these disclosures within ongoing clinical evaluations for inflammatory bowel disease management. The medical community is presented with comparative phase 2 metrics evaluating dual-targeting approaches against established single-target monotherapies.
While the coverage outlines the relative efficacy metrics reported at the presentation events, broader contextual implications regarding regulatory timelines or commercialization schedules are not currently established in the source material. Future developments will depend on subsequent trial phases and regulatory review processes, though current coverage does not yet specify dates for subsequent clinical milestones. Observers and stakeholders will monitor how these phase two findings for ABBV-466 translate into advanced-stage clinical development, alongside continued real-world data collection for Skyrizi and Rinvoq across inflammatory bowel disease indications. Readers must look to future announcements for definitive timelines regarding regulatory submissions or expanded clinical trial readouts.
Synthesized by PULSE from the headlines below under a strict no-invention contract. ✓ fact-checked: all claims supported by sources Updated 27d ago.
Quick answers
What is ABBV-466?
ABBV-466 is a novel dual-targeting therapy developed by AbbVie for moderate to severe Crohn's disease.
What did the phase 2 trial for ABBV-466 demonstrate?
Coverage indicates it demonstrated higher endoscopic remission rates than either anti-IL-23 or anti-beta-7 monotherapy, achieving a 40.5% remission rate.
Which other AbbVie treatments were discussed in the coverage?
Data for Skyrizi (risankizumab) and Rinvoq (upadacitinib) were highlighted regarding long-term clinical and endoscopic outcomes at UEGW 2026.
Coverage (5)
- AbbVie Presents Data for ABBV-466, a Novel Dual-Targeting Therapy Demonstrating Higher Endoscopic Remission Rates Than Either Anti-IL-23 or Anti-?4?7 Monotherapy in Moderate to Severe Crohn's Disease Investing News Network · 29d ago
- SKYRIZI® (risankizumab) and RINVOQ® (upadacitinib) Data Highlight Long-Term Clinical and Endoscopic Outcomes Across Inflammatory Bowel Disease (IBD) at UEGW 2026 Yahoo Finance · 29d ago
- Subcutaneous Risankizumab Induction Improved Outcomes in Crohn's Disease MedPage Today · 29d ago
- AbbVie ABBV-466 Achieves 40.5% Crohn's Remission grafa.com · 29d ago
- AbbVie’s next-gen Crohn’s disease combo beats Skyrizi in phase 2 trial Fierce Biotech · 29d ago
Topics
Related trends
After $10.9B exit to AbbVie, Apogee execs join Paragon to scale its R&D, company creation engine
Former Apogee executives join Paragon Labs to scale R&D following an acquisition, while Alaunos Therapeutics secures major financing.
Genmab’s latest phase 2 data spur claim ADC is ‘clearly superior’ to AbbVie’s Elahere
Genmab releases new phase 2 data for its antibody-drug conjugate, prompting claims of superiority over rival treatments.
AbbVie's Cerevel buyout delivers as FDA gives go-ahead to 1st-in-class Juvmo in Parkinson's disease
The FDA has approved Juvmo, a first-in-class Parkinson's disease medication, validating AbbVie's $8.7 billion acquisition of Cerevel.
New Parkinson’s drug approved in the US: What does it do differently?
The U.S. FDA has approved AbbVie's Juvmo, a first-in-class medication designed to provide a next-generation treatment option for Parkinson's disease.
Decades-old puzzle solved as scientists uncover cause of inflammatory bowel disease
A genetic link to IBD has been pinpointed after decades of uncertainty—here’s what’s driving the breakthrough
AbbVie Revenue Rises on Strength in Immunology, Neuroscience
AbbVie reports Q3 2026 sales performance aligned with analyst estimates, driven by growth in its immunology and neuroscience portfolios.